The broad therapeutic potential of novel IgM hexamer antibodies is still vastly undiscovered. Although hexamers were discovered decades ago, their limited natural creation and short shelf life make them a challenge to explore in research and clinical settings. However, this begs the question of what their broad therapeutic potential could be.

I challenged myself to create a sleek, modern, and clean visual identity for a female-founded and women-led biotech working to develop first-in-class immunotherapies with hexamer antibodies. Why? Just like hexamers face industry challenges, so do female-founded and women-led biotechs and life sciences companies. According to Nature Biotechnology, in 2020, one in four US-based biotech startups had a female founder. Approximately 40% of biotech startups had at least one woman on their Board of Directors, and ~42% had at least one woman in an executive position. According to Forbes, in 2021, women represented ~23% of biotech CEOs, and in 2023, for the first time in US history, women represented a mere 10% of Fortune 500 company CEO roles. An abysmal 3% of VC funding goes to businesses founded by women. This is despite statistics demonstrating that in 2023, female founders of tech companies generated 35% higher ROI than their male counterparts.

While strides have been made on both hexamer discovery and gender equality fronts, there is still room for more. That's where Adaptiv Immunology rises to the challenge, both old and new.

​

To learn more about diversity in corporate leadership, check out E.L.F.'s Diversity campaign and this coordinating article by Fast Company.